Cargando…
405例肺癌合并肺结核患者临床特征及驱动基因检测分析
BACKGROUND AND OBJECTIVE: New treatment methods such as targeted therapy and immune checkpoint inhibitors have been applied to lung cancer patients. It is necessary to further understand the patients with lung cancer combined with pulmonary tuberculosis with the development of lung cancer research....
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260389/ https://www.ncbi.nlm.nih.gov/pubmed/32336065 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.25 |
_version_ | 1783540301868040192 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: New treatment methods such as targeted therapy and immune checkpoint inhibitors have been applied to lung cancer patients. It is necessary to further understand the patients with lung cancer combined with pulmonary tuberculosis with the development of lung cancer research. The purpose of this study was to analyze the clinical characteristics of lung cancer patients with pulmonary tuberculosis, the status of driver genes, and their relationships. METHODS: A retrospective analysis was performed on 405 patients with lung cancer and pulmonary tuberculosis hospitalized in our hospital from January 2014 to December 2019. The relationship between clinical characteristics and driver genes status was analyzed. RESULTS: Among the 405 patients with lung cancer combined with pulmonary tuberculosis, 77.3% were male and 85.3% were patients with a history of smoking. The pathological type was mainly lung adenocarcinoma. When there were cavities in chest computed tomography (CT), squamous cell carcinoma was the main type. 214 patients underwent driver genes testing. The epidermal growth factor receptor (EGFR) gene mutation rate was 35.9%, of which 41.8% were exon 19 deletion mutations and 50.9% were exon 21 L858R mutations. When there were cavities in the chest CT, the EGFR mutation rate was significantly reduced (16.1%). The positive rate of anaplastic lymphoma kinase (ALK) fusion gene detection was 2.5%, the mutation rate of c-ros oncogene 1 receptor kinase (ROS1) gene was 1.9%, the mutation rate of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene was 1.1%, and the mutation rate of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene was 10.1%. The genetic mutation rate of female patients with lung cancer and pulmonary tuberculosis was 50.0%, and that of men was 27.9%. CONCLUSION: Patients with lung cancer and pulmonary tuberculosis are predominantly male with smoking history. Adenocarcinoma is the most common pathological type. The positive rate of gene mutation was not significantly different from that of simple lung cancer, but when there were cavities in the chest image, the genetic mutation rate was significantly reduced. |
format | Online Article Text |
id | pubmed-7260389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-72603892020-06-08 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: New treatment methods such as targeted therapy and immune checkpoint inhibitors have been applied to lung cancer patients. It is necessary to further understand the patients with lung cancer combined with pulmonary tuberculosis with the development of lung cancer research. The purpose of this study was to analyze the clinical characteristics of lung cancer patients with pulmonary tuberculosis, the status of driver genes, and their relationships. METHODS: A retrospective analysis was performed on 405 patients with lung cancer and pulmonary tuberculosis hospitalized in our hospital from January 2014 to December 2019. The relationship between clinical characteristics and driver genes status was analyzed. RESULTS: Among the 405 patients with lung cancer combined with pulmonary tuberculosis, 77.3% were male and 85.3% were patients with a history of smoking. The pathological type was mainly lung adenocarcinoma. When there were cavities in chest computed tomography (CT), squamous cell carcinoma was the main type. 214 patients underwent driver genes testing. The epidermal growth factor receptor (EGFR) gene mutation rate was 35.9%, of which 41.8% were exon 19 deletion mutations and 50.9% were exon 21 L858R mutations. When there were cavities in the chest CT, the EGFR mutation rate was significantly reduced (16.1%). The positive rate of anaplastic lymphoma kinase (ALK) fusion gene detection was 2.5%, the mutation rate of c-ros oncogene 1 receptor kinase (ROS1) gene was 1.9%, the mutation rate of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene was 1.1%, and the mutation rate of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene was 10.1%. The genetic mutation rate of female patients with lung cancer and pulmonary tuberculosis was 50.0%, and that of men was 27.9%. CONCLUSION: Patients with lung cancer and pulmonary tuberculosis are predominantly male with smoking history. Adenocarcinoma is the most common pathological type. The positive rate of gene mutation was not significantly different from that of simple lung cancer, but when there were cavities in the chest image, the genetic mutation rate was significantly reduced. 中国肺癌杂志编辑部 2020-05-20 /pmc/articles/PMC7260389/ /pubmed/32336065 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.25 Text en 版权所有©《中国肺癌杂志》编辑部2020 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 临床研究 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 |
title | 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 |
title_full | 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 |
title_fullStr | 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 |
title_full_unstemmed | 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 |
title_short | 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 |
title_sort | 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260389/ https://www.ncbi.nlm.nih.gov/pubmed/32336065 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.25 |
work_keys_str_mv | AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī |